Search research articles
Contact Us
Filters
Showing results (181-190 of 319) with videos related to
Page
of 32
Sort By:
Frontiers in Immunology
|
June 18, 2021
Hemadsorption as a Treatment Option for Multisystem Inflammatory Syndrome in Children Associated With COVID-19. A Case Report
Juan Carlos Ruiz-Rodríguez, Luis Chiscano-Camón, Clara Palmada, et al.
Archivos De Bronconeumologia
|
September 27, 2022
Hyperglycemia in Acute Critically Ill COVID-19 Patients
Catia Cilloniz, Juan M Pericàs, Anna Motos, et al.
Frontiers in Immunology
|
December 6, 2021
JAK2-STAT Epigenetically Regulates Tolerized Genes in Monocytes in the First Encounter With Gram-Negative Bacterial Endotoxins in Sepsis
Octavio Morante-Palacios, Clara Lorente-Sorolla, Laura Ciudad, et al.
Intensive Care Medicine
|
January 2, 2023
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
Pedro Póvoa, Luís Coelho, Felipe Dal-Pizzol, et al.
Critical Care Explorations
|
October 16, 2020
Extracorporeal Membrane Oxygenation Retrieval in Coronavirus Disease 2019: A Case-Series of 19 Patients Supported at a High-Volume Extracorporeal Membrane Oxygenation Center
Jordi Riera, Eduard Argudo, María Martínez-Martínez, et al.
International Angiology : a Journal of the International Union of Angiology
|
November 9, 2021
Mortality and bleeding complications of COVID-19 critically ill patients with venous thromboembolism
Daniel Gil-Sala, Claudia Riera, Marvin García-Reyes, et al.
Antibiotics (Basel, Switzerland)
|
January 25, 2025
Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. <i>Antibiotics</i> 2024, <i>13</i>, 874
Cristina Kirkegaard-Biosca, Ester Del Barrio-Tofiño, Miguel Villamarín, et al.
Antibiotics (Basel, Switzerland)
|
September 28, 2024
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
Cristina Kirkegaard-Biosca, Ester Del Barrio-Tofiño, Miguel Villamarín, et al.
The Lancet. Infectious Diseases
|
October 15, 2020
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti, Roger Echols, Yuko Matsunaga, et al.
International Journal of Antimicrobial Agents
|
August 2, 2019
Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship?
Kordo Saeed, Juan González Del Castillo, Craig Backous, et al.
Page
of 32
Search research articles
Search
Showing results (181-190 of 319) with videos related to
Sort By:
Page
of 32
Frontiers in Immunology
|
June 18, 2021
Hemadsorption as a Treatment Option for Multisystem Inflammatory Syndrome in Children Associated With COVID-19. A Case Report
Juan Carlos Ruiz-Rodríguez, Luis Chiscano-Camón, Clara Palmada, et al.
Archivos De Bronconeumologia
|
September 27, 2022
Hyperglycemia in Acute Critically Ill COVID-19 Patients
Catia Cilloniz, Juan M Pericàs, Anna Motos, et al.
Frontiers in Immunology
|
December 6, 2021
JAK2-STAT Epigenetically Regulates Tolerized Genes in Monocytes in the First Encounter With Gram-Negative Bacterial Endotoxins in Sepsis
Octavio Morante-Palacios, Clara Lorente-Sorolla, Laura Ciudad, et al.
Intensive Care Medicine
|
January 2, 2023
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
Pedro Póvoa, Luís Coelho, Felipe Dal-Pizzol, et al.
Critical Care Explorations
|
October 16, 2020
Extracorporeal Membrane Oxygenation Retrieval in Coronavirus Disease 2019: A Case-Series of 19 Patients Supported at a High-Volume Extracorporeal Membrane Oxygenation Center
Jordi Riera, Eduard Argudo, María Martínez-Martínez, et al.
International Angiology : a Journal of the International Union of Angiology
|
November 9, 2021
Mortality and bleeding complications of COVID-19 critically ill patients with venous thromboembolism
Daniel Gil-Sala, Claudia Riera, Marvin García-Reyes, et al.
Antibiotics (Basel, Switzerland)
|
January 25, 2025
Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. <i>Antibiotics</i> 2024, <i>13</i>, 874
Cristina Kirkegaard-Biosca, Ester Del Barrio-Tofiño, Miguel Villamarín, et al.
Antibiotics (Basel, Switzerland)
|
September 28, 2024
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
Cristina Kirkegaard-Biosca, Ester Del Barrio-Tofiño, Miguel Villamarín, et al.
The Lancet. Infectious Diseases
|
October 15, 2020
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti, Roger Echols, Yuko Matsunaga, et al.
International Journal of Antimicrobial Agents
|
August 2, 2019
Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship?
Kordo Saeed, Juan González Del Castillo, Craig Backous, et al.
Page
of 32